It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC.
Questions
- Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? (0:11)
- What has the CheckMate 040 Cohort 5 study taught us about the clinical impact of nivolumab in these patients? (1:04)
- What did we learn from this meeting about the efficacy and safety of hepatic arterial infusion chemotherapy in combination with sintilimab? (2:32)
- Which of the advances in immune checkpoint inhibitors do you consider to be particularly promising? (4:03)
Disclosures: Dr Bruno Sangro has received consultancy and/ or speaker fees from Adaptimmune, AstraZeneca, Bayer, BMS, Boston Scientific, BTG, Eli Lilly, Ipsen, Roche, Sirtex and Terumo; and research grants (to Institution) from BMS and Sirtex.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
